Drug News Nov Issue 25

Total Page:16

File Type:pdf, Size:1020Kb

Drug News Nov Issue 25 D r u g N e w s 藥 物 情 報 Issue No. 25 : November 2011 This is a monthly digest of local and overseas drug safety news and information released in the previous month. For the latest news and information, please refer to public announcements or the website of the Drug Office of the Department of Health (http://www.drugoffice.gov.hk). Safety Update US: Updated information about drug Canada and FDA released similar alerts on the interaction of Zyvox (linezolid) and interaction between methylene blue and serotonin Methylene Blue with serotonergic reuptake inhibitors. At the same time, FDA also released alert on the interaction between linezolid psychiatric medications and serotonin reuptake inhibitors. The news had 20 October 2011 – The Food and Drug been reported in Issue No. 17 and 22 of Drug News Administration (FDA) provided additional respectively. In addition, the Department of Health information about the possible serotonin syndrome (DH) issued press statement on 18 February 2011 in patients taking serotonergic psychiatric and letters were also sent to healthcare professionals medications and linezolid/ methylene blue. It was in February 2011 and July 2011. found that not all serotonergic psychiatric drugs had The product certificate holders of the an equal capacity to cause serotonin syndrome with pharmaceutical products containing methylene blue, use of linezolid/ methylene blue. According to the linezolid and serotonergic psychiatric medications FDA's Adverse Event Reporting System (AERS), have been requested to update the sales pack and/or most cases of serotonin syndrome with linezolid or package insert of these products to include methylene blue occurred in patients taking specific information about the potential drug interactions. serotonergic psychiatric drugs, namely a selective DH will keep vigilance against this issue. serotonin reuptake inhibitor (SSRI) or a serotonin norepinephrine reuptake inhibitor (SNRI); and for EU: Safety review of Protelos and Osseor cases associated with methylene blue, also (strontium ranelate) clomipramine . It was still unclear whether linezolid or intravenous methylene blue administration in 20 October 2011 –The Committee for Medicinal patients receiving other psychiatric drugs with lesser Products for Human Use (CHMP) of the The degrees of serotonergic activity posed a comparable European Medicines Agency (EMA) was reviewing risk. Besides, cases associated with methylene blue data on the cardiovascular and cutaneous safety mostly occurred in the context of parathyroid concerns, taking into account existing risk- surgery which involved the intravenous minimisation measures to determine whether the administration of methylene blue as a visualizing cases of venous thromboembolism and drug rash agent with dose ranging from 1 mg/kg to 8 mg/kg. with eosinophilia and systemic symptoms would The risk in patients taking methylene blue by other have an impact on the benefit-risk profile and routes or at intravenous doses lower than 1 mg/kg conditions of use for Protelos and Osseor. At this remained unknown. juncture, there were no changes to the recommendations on the conditions for use of these In Hong Kong, Zyvox (linezolid) is registered by two drugs in Europe. Pfizer Corp. HK Ltd., and is a prescription medicine used for treatment of infections, including In Hong Kong, Protos Granules for Oral Suspension pneumonia and infections of skin. Methylene blue 2g containing strontium ranelate is registered by injection is registered by Sino-Asia Pharmaceutical Servier Hong Kong Ltd. and is a prescription Supplies Ltd. It is a non-poison used for treatment of medicine used for treatment of osteoporosis in methemoglobinemia. Earlier this year, both Health postmenopausal women and to reduce the risk of Drug Office, Page 1 Department of Health, Hong Kong SAR Safety Update fracture at spine & hips. As reported in Issue No. 23 was linked to clinical adverse events. However, the of Drug News, safety alert about serious skin recall was conducted as a precautionary measure reactions, namely Stevens-Johnson syndrome and because the defect could have led to slightly higher toxic epidermal necrolysis, with Protos had been levels of tacrolimus in the blood of patients taking released by the Health Sciences Authority (HSA) of the affected capsules. Singapore in August 2011. DH will keep vigilance In Hong Kong, Advagraf Prolonged-release Hard against this issue. Capsule 0.5mg is registered by Astellas Pharma EU: Positive benefit-risk balance of Hong Kong Company Ltd., and is a prescription angiotensin II receptor antagonists medicine used as an immunosuppressant for adult in remained preventing transplant rejection in kidney or liver allograft recipients and treatment of allograft 20 October 2011 – CHMP reviewed all available rejection that are resistant to treatment with other data in patients taking angiotensin II receptor immunosuppressants. The company confirmed that antagonists (ARBs) and concluded that the evidence the affected batches have not been distributed in did not support any increased risk of cancer in Hong Kong. patients using these medicines. The review was initiated as a meta-analysis which showed a small Canada, Australia, Singapore and US: increased risk of new cancers (particularly lung Risk of increased blood pressure and cancer) with ARBs compared with placebo and other heart rate associated with Strattera heart medicines (7.2% versus 6%). However, the (atomoxetine) CHMP found that the evidence from the meta- analysis was weak as there were several problems A recent analysis of combined data from Eli Lilly with the quality of the data and there was a sponsored controlled and uncontrolled clinical trials possibility of publication bias. The CHMP also indicated that in 8417 pediatric patients treated with reviewed data from other studies and the results did Strattera (atomoxetine), a selective norepinephrine not show an increased risk of cancer with ARBs. reuptake inhibitor, approximately 25% experienced an increase in blood pressure of 10 mmHg and 5-8% In Hong Kong, there are about 130 registered an increase of 20 mmHg while heart rate increased pharmaceutical products containing ARBs. They are by 10 bpm in 33% of patients and by 20 bpm in 12% prescription medicines used to treat hypertension. of patients. These increases had also been observed They may also be used in the management of heart in similar proportion of adult patients with Attention failure and diabetic nephropathy. FDA had also Deficit Hyperactivity Disorder (ADHD) which announced similar conclusion in June 2011 as could be a potential risk for some patients. reported in Issue No. 20 of Drug News. DH remains Following its release, safety alerts were issued by vigilant to any new findings about ARBs. Health Canada, TGA and HSA on 21 October, 2 EU: Precautionary recall of Advagraf 0.5 November and 8 November 2011 respectively. mg capsule batches (tacrolimus) Healthcare professionals were advised to observe the following recommendations: 20 October 2011 – EMA agreed to the immediate recall of some batches of 0.5 mg prolonged-release • Atomoxetine is contraindicated in patients with hard capsules of Advagraf (tacrolimus) from symptomatic cardiovascular diseases, moderate pharmacies and wholesalers across EU because an to severe hypertension or severe cardiovascular unexpected increase in release of active substance disorders whose condition would be expected from the capsules was detected during routine to deteriorate if they experienced increases in testing by the marketing-authorisation holder, blood pressure or in heart rate that could be Astellas. The company found that an average of 70% clinically important. of the tacrolimus in the capsules was released during • Atomoxetine should be used with caution in the first 1.5 hours of dissolution testing which was patients whose underlying medical conditions above the permitted range of 48% to 68%. The could be worsened by increases in blood available information did not suggest that the defect pressure or heart rate, such as patients with Drug Office, Page 2 Department of Health, Hong Kong SAR Safety Update hypertension, tachycardia, or cardiovascular or inquiries following an unpublished report about the cerebrovascular disease. detection of recombinant HPV L1-specific DNA sequences in 13 vials of Gardasil from different lots. • Atomoxetine should be used with caution in The Agency reassured that the presence of DNA patients with congenital or acquired long QT fragments was expected in Gardasil and not syndrome or a family history of QT evidence of contamination. FDA considered that prolongation. Gardasil continued to be safe and effective and its • Patients should be screened for pre-existing or benefits continued to outweigh its risks. The review underlying cardiovascular or cerebrovascular of all reports related to Gardasil vaccination in the conditions before initiation of treatment with Vaccine Adverse Event Reporting System showed atomoxetine and monitored during the course no evidence of unusual clinical patterns or high of treatment. reporting rates of adverse events, including autoimmune diseases. FDA would continue to • Heart rate and blood pressure should be monitor the safety of Gardasil. measured in all patients before atomoxetine is started, after the dose is increased, and In Hong Kong, Gardasil Vaccine Injection available periodically during treatment, particularly in pre-filled syringes and vials are registered by Merck Sharp & Dohme (Asia) Ltd. and are
Recommended publications
  • Antibiotic Practice Change to Curtail Linezolid Use in Pediatric Hospitalized Patients in Hawai‘I with Uncomplicated Skin and Soft Tissue Infections
    Antibiotic Practice Change to Curtail Linezolid Use in Pediatric Hospitalized Patients in Hawai‘i with Uncomplicated Skin and Soft Tissue Infections Cheryl Okado MD and Tori Teramae BS Abstract MRSA coverage, clindamycin became a widely-used antibi- otic for treating uncomplicated SSTIs in children. Following Antimicrobial resistance affects health care providers’ choice of antibiotics increasing clindamycin use, increasing clindamycin resistance in the treatment of skin and soft tissue infections (SSTIs). Based on local was soon noted, particularly in MRSA isolates.2 Prior to 2010, antibiotic susceptibility data showing high clindamycin resistance and high MRSA predominance appeared to peak, and since then it has MRSA prevalence, a change in antibiotic regimen for children hospitalized for 3 uncomplicated SSTIs was instituted in an attempt to curb the use of linezolid. been decreasing. The prevalence of clindamycin-resistant GAS A retrospective chart review was performed on 278 pediatric patients with has been known to vary with time and location with US rates uncomplicated SSTIs hospitalized at Kapi‘olani Medical Center for Women ranging from 4%-41% since the early 2000s.4 and Children in Hawai‘i from May 2014 to April 2015 and November 2015 to October 2016. Data consisted of 12 months of baseline data and 12 In Hawai‘i, methicillin and clindamycin resistance patterns of months of data post-implementation of an antibiotic combination regimen of SA initially followed similar increasing trends. Antibiograms 2 widely-used antibiotics: high-dose cefazolin and high-dose clindamycin. at Hawai‘i’s children’s hospital, Kapi‘olani Medical Center for Practitioners were encouraged to use cefazolin alone if clinical suspicion was high for single-organism infection with group A streptococcus.
    [Show full text]
  • Treatment of Drug-Resistant Tuberculosis an Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Payam Nahid, Sundari R
    AMERICAN THORACIC SOCIETY DOCUMENTS Treatment of Drug-Resistant Tuberculosis An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Payam Nahid, Sundari R. Mase, Giovanni Battista Migliori, Giovanni Sotgiu, Graham H. Bothamley, Jan L. Brozek, Adithya Cattamanchi, J. Peter Cegielski, Lisa Chen, Charles L. Daley, Tracy L. Dalton, Raquel Duarte, Federica Fregonese, C. Robert Horsburgh, Jr., Faiz Ahmad Khan, Fayez Kheir, Zhiyi Lan, Alfred Lardizabal, Michael Lauzardo, Joan M. Mangan, Suzanne M. Marks, Lindsay McKenna, Dick Menzies, Carole D. Mitnick, Diana M. Nilsen, Farah Parvez, Charles A. Peloquin, Ann Raftery, H. Simon Schaaf, Neha S. Shah, Jeffrey R. Starke, John W. Wilson, Jonathan M. Wortham, Terence Chorba, and Barbara Seaworth; on behalf of the American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America THIS OFFICIAL CLINICAL PRACTICE GUIDELINE WAS APPROVED BY THE AMERICAN THORACIC SOCIETY, THE EUROPEAN RESPIRATORY SOCIETY, AND THE INFECTIOUS DISEASES SOCIETY OF AMERICA SEPTEMBER 2019, AND WAS CLEARED BY THE U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION SEPTEMBER 2019 Background: The American Thoracic Society, U.S. Centers for was judged to be very low, because the data came Disease Control and Prevention, European Respiratory Society, and from observational studies with significant loss to follow-up Infectious Diseases Society of America jointly sponsored this new and imbalance in background regimens between comparator practice guideline on the treatment of drug-resistant tuberculosis groups. Good practices in the management of MDR-TB are (DR-TB). The document includes recommendations on the described. On the basis of the evidence review, a clinical strategy treatment of multidrug-resistant TB (MDR-TB) as well as tool for building a treatment regimen for MDR-TB is also isoniazid-resistant but rifampin-susceptible TB.
    [Show full text]
  • Frequently Asked Questions on The
    Frequently asked questions on the WHO treatment guidelines for isoniazid-resistant tuberculosis Version: 24 April 2018 The advice in this document has been prepared by the Global TB Programme of the World Health Organization (WHO) and is to be read alongside the WHO treatment guidelines for isoniazid-resistant tuberculosis and its online annexes. See Further reading ​ ​ at end for additional resources. Who are the new WHO treatment guidelines for isoniazid-resistant tuberculosis intended for ? ​ ​ The WHO treatment guidelines for isoniazid-resistant tuberculosis are targeted at health care ​ professionals (doctors, nurses) and other staff involved in TB care in both low and high resource settings. The possibility of drug-resistant disease now needs to be entertained whenever treating TB patients. These guidelines provide technical detail which is helpful in making the best-informed decision in clinical practice and programme management. The answers to the frequently asked questions (FAQ) in this document intend to help implementers with common, practical issues that arise when adopting the new guidance. This document complements the WHO guidelines by elaborating further on certain aspects of ​ implementation that were beyond the scope of the guideline itself. What are the main recommendations of these new guidelines ? The new guidelines recommend that patients with confirmed isoniazid-resistant and rifampicin susceptible tuberculosis (abbreviated to Hr-TB) are treated for 6 months with a regimen composed of ​ ​ rifampicin (R), ethambutol (E), pyrazinamide (Z) and levofloxacin (Lfx). The exclusion of rifampicin resistance ahead of start of this regimen is critical. It is further recommended not to add streptomycin (S) or other injectable agents to the treatment regimen.
    [Show full text]
  • Medications to Be Avoided Or Used with Caution in Parkinson's Disease
    Medications To Be Avoided Or Used With Caution in Parkinson’s Disease This medication list is not intended to be complete and additional brand names may be found for each medication. Every patient is different and you may need to take one of these medications despite caution against it. Please discuss your particular situation with your physician and do not stop any medication that you are currently taking without first seeking advice from your physician. Most medications should be tapered off and not stopped suddenly. Although you may not be taking these medications at home, one of these medications may be introduced while hospitalized. If a hospitalization is planned, please have your neurologist contact your treating physician in the hospital to advise which medications should be avoided. Medications to be avoided or used with caution in combination with Selegiline HCL (Eldepryl®, Deprenyl®, Zelapar®), Rasagiline (Azilect®) and Safinamide (Xadago®) Medication Type Medication Name Brand Name Narcotics/Analgesics Meperidine Demerol® Tramadol Ultram® Methadone Dolophine® Propoxyphene Darvon® Antidepressants St. John’s Wort Several Brands Muscle Relaxants Cyclobenzaprine Flexeril® Cough Suppressants Dextromethorphan Robitussin® products, other brands — found as an ingredient in various cough and cold medications Decongestants/Stimulants Pseudoephedrine Sudafed® products, other Phenylephrine brands — found as an ingredient Ephedrine in various cold and allergy medications Other medications Linezolid (antibiotic) Zyvox® that inhibit Monoamine oxidase Phenelzine Nardil® Tranylcypromine Parnate® Isocarboxazid Marplan® Note: Additional medications are cautioned against in people taking Monoamine oxidase inhibitors (MAOI), including other opioids (beyond what is mentioned in the chart above), most classes of antidepressants and other stimulants (beyond what is mentioned in the chart above).
    [Show full text]
  • Serotonin Syndrome Due to Co-Administration of Linezolid and Methadone
    Le Infezioni in Medicina, n. 3, 263-266, 2017 CASE REPORT 263 Serotonin syndrome due to co-administration of linezolid and methadone Antonio Mastroianni1, Gianfranco Ravaglia2 1U.O. Malattie Infettive, Presidio Ospedaliero, “G.B. Morgagni - L. Pierantoni”, Forlì, Italy; 2U.O. Farmacia, Presidio Ospedaliero “G.B. Morgagni - L. Pierantoni”, Forlì, Italy SUMMARY Serotonin syndrome (SS), a potentially life-threatening verity from mild to life-threatening. To our knowledge, adverse drug reaction caused by excessive serotoner- we present the first reported case of SS associated with gic agonism in central and peripheral nervous system linezolid and methadone with a brief review of the lit- serotonergic receptors, may be caused by a single drug erature. or a combination of drugs with serotonergic activity. The syndrome results in a variety of mental, autonom- Keywords: serotonin syndrome, linezolid, methadone, ic and neuromuscular changes, which can range in se- methicillin-resistant Staphylococcus aureus. n INTRODUCTION methadone. This serious adverse interaction be- tween linezolid and methadone inducing SS was erotonin syndrome (SS) is a toxic state caused reported in a drug-addict HIV-positive man with Smainly by excessive serotonergic activity in sepsis, osteomyelitis and multiple muscle abscess- the nervous system, nearly always caused by a es and metastatic skin abscesses caused by meth- drug interaction involving two or more “seroto- icillin-resistant Staphylococcus aureus (MRSA), un- nergic” drugs [1]. These include serotonin pre- der combined antibiotic treatment. cursors, serotonin agonists, serotonin releasers, serotonin reuptake inhibitors, monoaminoxidase inhibitors (MAOIs) and some herbal medicines. n CASE REPORT Linezolid is a weak, nonselective, reversible in- hibitor of MAOIs, and potentially may interact A 39-year-old drug-addict male was admitted to with MAOIs and adrenergic and serotonergic our department with fever (up to 39.5°C) and a agents.
    [Show full text]
  • ZYVOX (Linezolid) Injection (Linezolid) Tablets (Linezolid) for Oral Suspension
    ® ZYVOX (linezolid) injection (linezolid) tablets (linezolid) for oral suspension To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX formulations and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION ZYVOX I.V. Injection, ZYVOX Tablets, and ZYVOX for Oral Suspension contain linezolid, which is a synthetic antibacterial agent of the oxazolidinone class. The chemical name for linezolid is (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl] methyl]-acetamide. The empirical formula is C16H20FN3O4. Its molecular weight is 337.35, and its chemical structure is represented below: O O O N N O C C H N 3 F H ZYVOX I.V. Injection is supplied as a ready-to-use sterile isotonic solution for intravenous infusion. Each mL contains 2 mg of linezolid. Inactive ingredients are sodium citrate, citric acid, and dextrose in an aqueous vehicle for intravenous administration. The sodium (Na+) content is 0.38 mg/mL (5 mEq per 300-mL bag; 3.3 mEq per 200-mL bag; and 1.7 mEq per 100-mL bag). ZYVOX Tablets for oral administration contain 400 mg or 600 mg linezolid as film-coated compressed tablets. Inactive ingredients are corn starch, microcrystalline cellulose, hydroxypropylcellulose, sodium starch glycolate, magnesium stearate, hypromellose, polyethylene glycol, titanium dioxide, and carnauba wax. The sodium (Na+) content is 1.95 mg per 400-mg tablet and 2.92 mg per 600-mg tablet (0.1 mEq per tablet, regardless of strength).
    [Show full text]
  • Tuberculosis Drug Information Guide, 2Nd Edition
    Tuberculosis Drug Information Guide 2ND EDITION Edmund G. Brown Jr, Governor STATE OF CALIFORNIA Diana S. Dooley, Secretary CALIFORNIA HEALTH & HUMAN SERVICES AGENCY Ron Chapman, MD, MPH, Director DEPARTMENT OF PUBLIC HEALTH Tuberculosis Drug Information Guide 2ND EDITION Edmund G. Brown Jr, Governor STATE OF CALIFORNIA Diana S. Dooley, Secretary CALIFORNIA HEALTH & HUMAN SERVICES AGENCY Ron Chapman, MD, MPH, Director DEPARTMENT OF PUBLIC HEALTH DrugInfo_2ndEd_v9.indd 3 12/5/12 3:55 PM Tuberculosis Drug Information Guide, 2nd edition was created through a collaboration of the Curry International Tuberculosis Center (CITC) and the State of California Department of Public Health, Tuberculosis Control Branch (CDPH). CITC is a project of the University of California, San Francisco, funded by the Centers for Disease Control and Prevention (CDC). The development of this Guide was funded through CDC Cooperative Agreement U52 CCU 900454. Permission is granted for nonprofit educational use and library duplication and distribution. Suggested citation: Curry International Tuberculosis Center and California Department of Public Health, 2012: Tuberculosis Drug Information Guide, 2nd edition. This publication is available on the CITC website: http://www.currytbcenter.ucsf.edu/ tbdruginfo/ Design: Edi Berton Design DrugInfo_2ndEd_v9.indd 4 12/5/12 3:55 PM Contributors Acknowledgments Ann M. Loeffler, MD John S. Bradley, MD Pediatric Infectious Diseases Attending and Director of Pediatric Rady Children’s Hospital San Diego, San Diego, California Hospitalists at Randall Children’s Hospital at Legacy Emanuel, Daniel Deck, Pharm.D. Portland, Oregon Department of Pharmaceutical Services, Pediatric Tuberculosis Consultant, San Francisco General Hospital, California Curry International Tuberculosis Center, San Francisco, California David Forinash, RPh Randall Children’s Hospital at Legacy Emanuel, Portland, Oregon Charles A.
    [Show full text]
  • Formulary and Program Updates Effective 8/1/18
    Formulary and Program Updates Effective 8/1/18 Pharmacy & Therapeutics Committee Meeting May 22, 2018 6:30 – 8:00 PM Role Call VOTING MEMBERS NON-VOTING MEMBERS • David Konanc, MD • Carl Antolick III, PharmD • Matthew K. Flynn, MD • Tracy Linton, MPH • Jennifer Burch, PharmD • Dee Jones • Peter Robie, MD • Lucy Barreto, DDS, MHA • Tony Gurley, RPh, JD • Renee Jarnigan, RPh • Michael Spiritos, MD • Stephanie Morrison, PharmD • John B. Anderson, MD, MPH • John Engemann, MD • Joseph Shanahan, MD 2 Ethics Awareness & Conflict of Interest Reminder In accordance with the NC State Health Plan for Teachers and State Employees’ ethics policy, it is the duty of every member of the Pharmacy & Therapeutics Committee, whether serving in a vote casting or advisory capacity, to avoid both conflicts of interest and appearances of conflict. Does any Committee member have any known conflict of interest or the appearance of any conflict with respect to any manufacturers of any medication to be discussed at today’s meeting? Or, if during the course of the evaluation process if you identify a conflict of interest or the appearance of a conflict. If so, please identify the conflict or appearance of conflict and refrain from any undue participation in the particular matter involved. 3 Minutes from Previous Committee Meeting • Instead of having the Secretary read the minutes, copies have been distributed for your review. • They are located just after the conflict of interest statement in the P&T Booklet that was emailed out. • Are there any additions or corrections to the minutes? • If not, the minutes will stand approved as is.
    [Show full text]
  • Adverse Effects of Psychotropic Medication
    Adverse effects of psychotropic medication RACHEL BROWN CLINICAL LEAD PHARMACIST – CAMHS, MEDICINES ADVICE AND CLINICAL EFFECTIVENESS OXFORD HEALTH NHS FOUNDATION TRUST Antipsychotic-induced hyperprolactinaemia Serotonin Syndrome Antipsychotic-induced hyperprolactinaemia Hyperprolactinaemia with APs 4 Dopamine inhibits prolactin release via D2 stimulation; serotonin promotes prolactin release via 5HT2A stimulation All antipsychotics are D2 antagonists → block the effect of DA → prolactin levels rise In the case of (most) second generation (atypical) there is simultaneous inhibition of 5HT2A receptors so serotonin can no longer stimulate prolactin release – theoretically cancel effects out Low risk antipsychotics High risk antipsychotics Aripiprazole Amisulpride Quetiapine Risperidone Lurasidone Paliperidone Clozapine Sulpiride Asenapine “Typical” / first generation antipsychotics Olanzapine? Causes of elevated prolactin 6 Physiological causes: Pharmacological causes Pathological causes • Pregnancy • Lactation • Antipsychotics • Prolactinoma • Stress (PRL levels of up to about 700 • Antidepressants* • Other pituitary or hypothalamic mU/L in men and 900 mU/L in • Opiates tumours or lesions women) • Peripheral dopamine receptor blockers • Hypothyroidism • Circadian variation (levels are e.g. metoclopramide, domperidone • Polycystic ovary syndrome highest in morning) • Antihypertensives e.g. calcium channel • Severe renal or liver disease • Macroprolactin (large molecular blockers, methyldopa aggregates lacking biological • H2 antagonists
    [Show full text]
  • Linezolid (Zyvox®)
    Linezolid (Zyvox®) IV and PO Only Use requires formal ID Consult Activity: Coverage against Staphylococcus aureus (MSSA and MRSA), Streptococcus pneumoniae, VRE Criteria for Use: • Vancomycin (VAN) MIC ≥ 2 mg/L in MRSA pneumonia • Patient with allergy to beta-lactams/vancomycin and organism resistant to other antimicrobials • Significant VRE infections (i.e. isolated from a sterile site: blood, abscess) • Infections due to MRSA in patient with well documented intolerance to VAN (NOTE: Red man syndrome is not a serious intolerance to VAN) Formal ID consult for use in osteomyelitis or complicated skin and soft tissue infection and all indications that are not listed above Unacceptable Uses: • Empiric use when VRE has not been cultured or documented • Uncomplicated urinary tract infection • Positive respiratory culture for VRE • VRE colonization Dosing in Adults: • Standard dose: 600 mg PO or IV Q12H In patients tolerating PO medications, should be given orally Oral formulation is completely absorbed and has 100% availability • No renal or hepatic dose adjustment Monitoring: • CBC at baseline and weekly (MONITOR platelets at baseline and weekly) Considerations for Use: • Caution in patients with thrombocytopenia. 3 percent of patients were noted to have a platelet decrease <75% of baseline or lower limit of normal in controlled trials (therapy <28 days, most < 21 days). Thrombocytopenia is reversible upon discontinuation and is correlated with duration • Linezolid is a weak MAOI. Use in caution with decongestants (i.e. pseudoephedrine) and
    [Show full text]
  • UWHC Guidelines for the Use of Linezolid (Zyvox )
    UWHC Guidelines for the Use of Linezolid (Zyvox®) Guidelines developed by UWHC Center for Drug Policy (CDP) Authors: Deborah Dunham, MA, RPh; Sarah E. Bland, RPh Coordination: Lee Vermeulen, MS, RPh, Director, CDP Reviewed by: William Craig, MD; Barry Fox, MD; Dennis Maki, MD; George Mejicano, MD; Carol A. Spiegel, PhD Originally Approved by P&T Committee: July 2000 Last Revised: August 2009 Next Scheduled For Review: August 2011 A. Background Because of the increase in multi-drug-resistant strains of gram-positive bacteria, the development of new and novel-acting antimicrobial agents is at the forefront of pharmaceutical research. Currently, the prevalence of methicillin-resistant staphylococci (MRSA) and vancomycin-resistant enterococci (VRE) is a major clinical problem. Linezolid (Zyvox®-Pfizer) is an antimicrobial agent of the oxazolidinone class that possesses a wide spectrum of activity against gram-positive organisms, including MRSA and VRE. Because of linezolid’s novel mechanism of action, cross-resistance with other antimicrobial agents is not expected. Linezolid is therefore a viable option for certain types of infectious disease. B. Appropriate Indications Linezolid has limited therapeutic applications at UW Hospital and Clinics. Appropriate use of linezolid will require a culture/susceptibility test with positive identification of an organism that demonstrates definitive resistance to all other possible antimicrobial agents. Based on the potential for bacterial resistance associated with the use of linezolid, the UW Pharmacy and Therapeutics Committee has approved its use in the following conditions: 1.0 Vancomycin-resistant Enterococcus faecium infections (not colonization), including those with concurrent bacteremia. 2.0 Methicillin-resistant S aureus infections (MRSA) in patients unable to tolerate vancomycin therapy or with serious pneumonia with MRSA.
    [Show full text]
  • Linezolid 2 Mg/Ml Solution for Infusion
    NA LINEZOLID IE LINEZOLID NA Package leaflet: Information for the user Numbness, tingling or blurred vision have been reported by patients • Decrease of the blood cell count pathogens. Specific therapy against Gram negative organisms must be Patients with hepatic insufficiency: Patients with mild to moderate - medicines used to treat moderate to severe pain, such as pethidine are pregnant, think you may be pregnant or are planning to have a baby, who have been given Linezolid for more than 28 days. If you experience • Weakness and/or sensory changes initiated concomitantly if co-infection with a Gram negative pathogen is hepatic insufficiency (Child-Pugh class A or B): No dose adjustment is Linezolid 2 mg/ml solution for infusion - medicines used to treat anxiety disorders, such as buspirone ask your doctor or pharmacist for advice before taking this medicine. difficulties with your vision you should consult your doctor as soon as Reporting of side effects documented or suspected. required. - an antibiotic called rifampicin You should not breast-feed when taking Linezolid because it passes into possible. If you get any side effects, talk to your doctor or pharmacist or nurse. This Description Patients with severe hepatic insufficiency (Child-Pugh class C): As Linezolid Take special care with Linezolid breast milk and could affect the baby. Other side effects include: includes any possible side effects not listed in this leaflet. You can also For single use only. The bag holds 300 ml solution and is packaged in a linezolid is metabolised by a non-enzymatic process, impairment of report side effects directly via HPRA Pharmacovigilance, Earlsfort Terrace, box.
    [Show full text]